首页 > 市场调查报告书 > 医疗设备

药物递输设备 DDS

市场调查报告书

商品编码

1532613

药物器材组合产品市场规模 - 按产品、应用、最终用途和全球预测，2024 年 - 2032 年

Drug Device Combination Products Market Size - By Product, Application, End-use & Global Forecast, 2024 - 2032

出版日期: 2024年05月28日 | 出版商:

Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在技术进步和研发力度加大的推动下，药物器材组合产品市场规模预计从 2024 年到 2032 年复合年增长率将达到 7.8%。最近，製造商正在将尖端技术整合到药物器械组合产品中，以提高其有效性和用户便利性。正在进行的研究正在帮助开发更精确、更可靠的设备，以改善药物传输和患者治疗结果。

因此，对技术和创新的投资正在推动发展，以确保这些产品在治疗一系列疾病方面变得更加复杂和有效。例如，2022年12月，Terumo公司与Kyowa Kirin合作推出了药物设备组合「G-Lasta皮下注射3.6毫克BodyPod」。本产品将自动注射器与聚乙二醇非格司亭结合起来，以减少化疗患者的发烧性嗜中性白血球减少症。

药物器材组合产品市场分为产品、应用、最终用途和区域。

在产品方面，由于先进技术与药物输送系统的高度整合以改善治疗效果，因此吸入器领域预计从 2024 年到 2032 年将录得显着的复合年增长率。製造商正在开发新型吸入器，将精密设备与药物结合，以更有效地管理呼吸系统疾病。此外，整合智慧技术等功能来追踪使用情况并确保正确用药依从性的不断进步将推动该细分市场的成长。

从应用来看，在改善患者治疗效果的需求不断增长的推动下，心血管疾病领域的药物器械组合产品产业预计到 2032 年将会成长。这些产品透过结合药物和设备来提供创新的解决方案，以解决各种心血管疾病。此外，医疗专业人员正在利用这些先进的组合来提高治疗效果和患者的依从性。正在进行的研究也正在塑造心血管疾病的治疗方式，以期为个人提供更量身定制和更有效的治疗方法。

从地区来看，在人口老化加剧和慢性病盛行率激增的推动下，亚太地区药物器械组合产品市场规模预计将在 2024 年至 2032 年间呈现强劲成长。亚太地区的研究人员正在开发先进的组合产品，以满足老年人和慢性病患者日益增长的医疗保健需求。的发展。

产业生态系统分析
产业影响力
- 成长动力
  - 对微创给药装置的需求不断增加
  - 技术进步
  - 慢性病盛行率增加
- 产业陷阱与挑战
  - 与药物器械组合产品相关的高成本
  - 药物传递的技术挑战
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
药物洗脱支架
- 冠状动脉药物支架
- 週边药物洗脱支架
点滴帮浦
- 植入式输液泵
- 胰岛素输注泵
- 病人自控镇痛泵
- 流动输液帮浦
- 容量输液泵
- 一次性使用输液泵
光动力疗法
伤口护理组合产品
预充式註射器
- 单室预灌封注射器
- 双室预灌封注射器
- 客製化预灌封注射器
药物洗脱球囊
- 冠状动脉药物洗脱球囊
- 週边药物洗脱球囊
雾化器
吸入器
- 药物粉末吸入器 (DPI)
- 定量吸入器 (MDI)
- 软雾吸入器 (SMI)
经皮给药系统
- 主动透皮系统
- 被动透皮系统
骨科组合产品
- 骨移植植入物
- 抗生素骨水泥
抗菌导管
- 泌尿导管
- 心血管导管
- 其他导管
其他产品

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
心血管疾病
糖尿病
呼吸系统问题
癌症治疗
抗菌应用
其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院和诊所
门诊手术中心
家庭护理设置
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abbott Laboratories
AbbVie, Inc.
Alcon, Inc.
Bausch Health Companies Inc
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Boston Scientific Corporation
GlaxoSmithKline plc
Johnson & Johnson
Kaleo, Inc.
Medtronic plc
Novartis AG
SINOMED
Smith & Nephew plc
Teleflex Incorporated
Teva Pharmaceutical Industries Ltd.

简介目录

Product Code: 9674

Drug Device Combination Products Market size is projected to record 7.8% CAGR from 2024 to 2032, driven by technological advancements and increasing R&D efforts. Of late, manufacturers are integrating cutting-edge technologies into drug device combination products to enhance their effectiveness and user convenience. Ongoing research is helping in developing more precise and reliable devices to improve drug delivery and patient outcomes.

Consequently, investments in technology and innovation are driving developments for ensuring that these products become more sophisticated and effective in treating a range of conditions. For instance, in December 2022, Terumo Corporation in collaboration with Kyowa Kirin introduced a drug-device combination "G-Lasta Subcutaneous Injection 3.6 mg BodyPod". This product combines an automated injector with pegfilgrastim to reduce febrile neutropenia in chemotherapy patients.

The drug device combination products market is segregated into product, application, end-use, and region.

In terms of product, the inhalers segment is expected to record significant CAGR from 2024 to 2032 due to the high integration of advanced technologies with medication delivery systems to improve treatment outcomes. Manufacturers are developing new inhalers that combine precision devices with medications to manage respiratory conditions more effectively. Moreover, the increasing advancements for incorporating features like smart technology to track usage and ensure proper medication adherence will drive the segment growth.

By application, the drug device combination products industry from the cardiovascular disorders segment is projected to rise through 2032, driven by increasing demand to improve patient outcomes. These products are providing innovative solutions by combining drugs and devices to address various cardiovascular conditions. Additionally, medical professionals are utilizing these advanced combinations to enhance treatment efficacy and patient compliance. Ongoing research is also shaping the way cardiovascular disorders are treated for promising more tailored and effective therapies for individuals.

Regionally, the Asia Pacific drug device combination products market size is projected to exhibit robust growth between 2024 and 2032, fueled by the increasing aging population and surging prevalence of chronic diseases. Researchers in APAC are developing advanced combination products to address the growing healthcare needs of older adults and those with chronic conditions The continuous advancements for enhancing combination products with improvements in drug delivery systems and integration with digital health technologies will boost the regional industry development.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for minimally invasive drug delivery devices
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Increasing prevalence of chronic diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with drug device combination products
  - 3.2.2.2 Technical challenges in drug delivery
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Drug-eluting stents
- 5.2.1 Coronary drug-elating stents
- 5.2.2 Peripheral drug-eluting stents
5.3 Infusion pumps
- 5.3.1 Implantable infusion pumps
- 5.3.2 Insulin infusion pumps
- 5.3.3 Patient-controlled analgesia pumps
- 5.3.4 Ambulatory infusion pumps
- 5.3.5 Volumetric infusion pumps
- 5.3.6 Disposable infusion pumps
5.4 Photodynamic therapy
5.5 Wound care combination product
5.6 Prefilled syringes
- 5.6.1 Single-chamber prefilled syringes
- 5.6.2 Dual-chamber prefilled syringes
- 5.6.3 Customized prefilled syringes
5.7 Drug-eluting balloons
- 5.7.1 Coronary drug-eluting balloons
- 5.7.2 Peripheral drug-eluting balloons
5.8 Nebulizers
5.9 Inhalers
- 5.9.1 Drug powdered inhalers (DPIs)
- 5.9.2 Metered dose inhalers (MDIs)
- 5.9.3 Soft mist inhalers (SMIs)
5.10 Transdermal delivery systems
- 5.10.1 Active transdermal systems
- 5.10.2 Passive transdermal systems
5.11 Orthopedic combination products
- 5.11.1 Bone graft implants
- 5.11.2 Antibiotic loaded bone cement
5.12 Antimicrobial catheters
- 5.12.1 Urological catheters
- 5.12.2 Cardiovascular catheters
- 5.12.3 Other catheters
5.13 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cardiovascular disorders
6.3 Diabetes
6.4 Respiratory problems
6.5 Cancer treatment
6.6 Antimicrobial application
6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Ambulatory surgical centers
7.4 Home care settings
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa